Press Release

Celyad Completes $100 Million IPO

July 27, 2015

Boston – July 27, 2015 – Cooley advised the underwriters on Celyad SA's initial public offering of American Depositary Shares (ADSs) and concurrent private placement in Europe. Celyad, based in Belgium, is a clinical-stage specialty biopharmaceutical company focused on changing the fields of cardiology and oncology by developing novel cell therapy treatment platforms called C-Cure and CAR-NKG2D. The company's ADSs trade on The NASDAQ Global Market under the symbol "CYAD."

UBS Securities LLC and Piper Jaffray & Co. acted as joint book-running managers of the global offering and as representatives of the several underwriters, including Petercam NV/SA, Bryan, Garnier & Co., LifeSci Capital, LLC and Lake Street Capital Markets, LLC.

About Cooley LLP

High-growth and established companies, investors and investment banks focused on technology and life sciences partner with Cooley on transformative deals and high-stakes matters, where innovation meets the law.

Cooley has 850 lawyers across 12 offices in the United States, China and Europe.